Jiangsu Kanion Pharmaceutical Co. Ltd. Class ASSE: 600557

"Jiangsu Kanion Pharmaceutical Co., Ltd."Semi-annual Report for 2026

Aug 28, 2026 · Issued by Jiangsu Kanion Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange

Semi-annual Report for 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Jiangsu Kanion Pharmaceutical Co. Ltd. Class A

"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Receipt of the Clinical Trial Approval Notice for Qihuang Zhengqi GranulesJul 22
"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Initially Repurchasing Shares through Call AuctionJul 17
"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Inclusion of Certain Pharmaceutical Products of the Company in the National Essential Medicines ListJul 10
"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call AuctionJul 4

All Jiangsu Kanion Pharmaceutical Co. Ltd. Class A news releases